tirzepatide type 1 diabetes trial as Adjunct to Insulin in Adults With and Overweight or Obesity: A Systematic Review of Randomized and Real‐World Evidence Efficacy and safety of tirzepatide
Description
The study was conducted in collaboration with Professor Kiyohide Fushimi, Department of Health Policy and Informatics, Science Tokyo
00188-7/asset/2c20a909-3c0e-4be2-9bc4-c699b73fc56e/main.assets/gr2_lrg.jpg)
J Biol Sci

Gastrointestinal adverse events only led to discontinuation in the semaglutide group (2.2%)

Finan, B., Yang, B., Ottaway, N